New

AI v2.0 Beta Launched. Experience the future of pharmaceutical care.

Try Now
Drug info language
Switches all medical info on this page (labels, indications, leaflet) without changing the rest of the interface.
Regulated (List II)Translated

ROVIL CAPS

200MG/Soft Capsule/IBUPROFENE
ROVAC
ManufacturerVerified lab

ROVAC

Public retail price
N/ADZD
Reference price (TR): 350.00 DZD

Identification

Active ingredient (INN)
IBUPROFENE
Internal code
04 B 084
Country of Origin
Algeria
Pharmaceutical form
Soft Capsule
Prescription List
Regulated (List II)
Packaging
B/20
ROVIL CAPS
Clinical View

DAWA Clinical Workbench v2.0

Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.

Indications

is indicated in adolescents and children from 20 kg body weight and 6 years of age and older for short-term symptomatic treatment of moderate acute pain and for short-term symptomatic treatment of fever if intravenous administration is clinically justified, when other routes of administration are not possible.

Associated Conditions

The following are the conditions for the treatment of the disease: The combination of gastrointestinal hemorrhages, ulcerations or perforations, sometimes fatal, has been reported with all NSAIDs, with or without signs of serious gastrointestinal events or a history of serious gastrointestinal events.

The risk of bleeding, ulceration or gastrointestinal perforation increases with the dose of NSAIDs used in patients with a history of ulceration, particularly in patients with complications such as haemorrhage or perforation of the disease.

These patients should start treatment with the lowest possible dose of gastrointestinal haemorrhage, gastrointestinal perforation or gastrointestinal perforation (e.g. misoprostol or proton pump inhibitors) and also in patients with a particular disorder that requires a certain risk of developing a disorder or a certain risk of developing a disorder of a disease.

Mechanism of Action

and collagen.

Experimental data suggest that l-ibuprofen inhibits the effect of low-dose acetylsalicylic acid on platelet aggregation in concomitant administration.

Adverse Effects

(e.g., a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive disorder, a hypertensive.

Alternatives